Alyssum Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
626 Massachusetts Ave Fl 2, Cambridge, M...Website
www.alyssumtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Alyssum Therapeutics
Alyssum Therapeutics is focused on pioneering B cell immunotherapy to regulate the B cell immune response for treating complex diseases. Their lead candidate, AT1965, is currently in Phase 1 clinical trials for advanced solid malignancies, showing promise in regressing hard-to-treat tumors. The company aims to transform patient lives by modulating B cells, which play a crucial role in the immune response against various conditions, including cancer and autoimmune diseases. Their innovative approach seeks to enhance survival outcomes in patients with solid tumors through comprehensive immune activation.Explore more
Popular SearchesAlyssum Therapeutics IncSIC Code 28,283NAICS Code 32,325Show moreAlyssum Therapeutics Org Chart
AB
Lead, Clinical Operations
TA
Chief Development Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alyssum Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Alyssum Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Alyssum Therapeutics has new funding data
Alyssum Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Alyssum Therapeutics is spiking on competitors!
Check if Alyssum Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Alyssum Therapeutics
Click to see if Alyssum Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Alyssum Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Alyssum Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Alyssum Therapeutics
Compare insights from companies similar to Alyssum Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alyssum Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alyssum Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alyssum Therapeutics.
Alyssum Therapeutics financials insights
Gather financial insights about Alyssum Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$26.5M
Alyssum Therapeutics Tech Stack
A closer look at the technologies used by Alyssum Therapeutics
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Project
Product Development, Research & Development, Medical Research, Pharmaceuticals, Clinical Operations
Project
Alyssum Therapeutics News & Media
Alyssum Therapeutics closes Series A and emerges from stealth mode as a clinical stage B cell immunology company
• A clinical stage B cell immunotherapy company for cancer and autoimmune diseases • Alyssum team has collectively developed over twenty clinical therapeutics CAMBRIDGE, MA, UNITED STATES, October 23, 2024 /EINPresswire.com/ -- Alyssum Therapeutics, …Alyssum Therapeutics Announces First Patient Dosed in Phase 1/2 Study of AT-1965, a CMTR2 Inhibitor, in Solid Tumors
B cell immunotherapy for solid cancer CAMBRIDGE, MA, USA, April 10, 2024 /EINPresswire.com/ -- Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate B cells, today announced the first patient was …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alyssum Therapeutics
Sign Up For FreeTo access detailed company insights
Alyssum Therapeutics is focused on pioneering B cell immunotherapy to regulate the B cell immune response for treating complex diseases. Their lead candidate, AT1965, is currently in Phase 1 clinical trials for advanced solid malignancies, showing promise in regressing hard-to-treat tumors. The company aims to transform patient lives by modulating... Read More
